In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features

BACKGROUND: The development of molecularly tailored therapeutic agents such as the BCR/ABL-active tyrosine kinase inhibitors (TKi) resulted in an excellent treatment option for chronic myeloid leukemia (CML) patients. However, following TKi discontinuation, disease relapses in 40–60% of patients, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Tusa, Ignazia, Cheloni, Giulia, Poteti, Martina, Silvano, Angela, Tubita, Alessandro, Lombardi, Zoe, Gozzini, Antonella, Caporale, Roberto, Scappini, Barbara, Dello Sbarba, Persio, Rovida, Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568716/
https://www.ncbi.nlm.nih.gov/pubmed/32780298
http://dx.doi.org/10.1007/s11523-020-00741-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568716/
https://www.ncbi.nlm.nih.gov/pubmed/32780298
http://dx.doi.org/10.1007/s11523-020-00741-x

Ejemplares similares